Popular Articles

New York Becomes First State To Allow Payment For Donating Eggs For Stem Cell Research
New York"s Empire State Stem Cell Board earlier this month decided to allow embryonic stem cell researchers who receive state funding to compensate women for donating their eggs for use in research, making New York the first state to enact such a policy, the Washington Post reports (Stein, Washington Post, 6/26). According to the New York Times, the New York state Legislature in 2007 allotted $600 million for an 11-year stem cell research plan (Nelson, New York Times, 6/26). Under the board"s decisions, researchers receiving the state funding may pay women up to $10,000 to compensate them for the time, discomfort and expenses associated with egg donation. David Hohn, vice chair of the board"s two committees that endorsed the decision, said that the board "could not distinguish ethically between the payment for in vitro fertilization, which is very well precedented, and the compensation for donation for research." The board said researchers should follow the same guidelines as infertility clinics that receive donated eggs for infertile couples. Under those guidelines, payments exceeding $5,000 must be justified, and those exceeding $10,000 are considered excessive (Washington Post, 6/26). Robert Klitzman, director of the master"s degree program in bioethics at Columbia University and a member of the stem cell board"s ethics committee, said the payments will be carefully evaluated by an institutional review board (New York Times, 6/26).The Post reports that the decision goes against policies in other states that offer funding for embryonic stem cell research, as well as against current guidelines from scientific organizations like the National Academy of Sciences (Washington Post, 6/26). NAS guidelines, for example, prohibit paying women for eggs used in stem cell research. Similarly, the internal guidelines for New York-based groups like Rockefeller University, Cornell University and the Sloan-Kettering Institute prohibit financial compensation for donated eggs. However, researchers say that efforts to recruit unpaid donors have been unsuccessful and that the board"s decision will give New York an advantage in stem cell research (New York Times, 6/26). The decision was welcomed by scientists and other proponents of stem cell research, who said it will allow them to further research in areas like therapeutic cloning. The process, also known as somatic cell nuclear transfer, involves replacing the genetic material in a human egg with genes from the nucleus of a patient"s cell. The egg is then developed into an early embryo, which, in theory, could be used to produce stem cells that the patient"s immune system would not reject. Although the procedure has been unsuccessful so far, researchers say the board"s decision will help attract more donors, which will allow for more experiments. Egg donation involves weeks of hormone injections to stimulate the ovaries and a painful egg extraction procedure, which carries rare but serious risks. Other attempts at soliciting women to donate eggs for stem cell research have been unsuccessful, according to the Post.Some critics of the board"s decision said that paying women for eggs could lead to exploitation, especially for low-income women. Thomas Berg -- a Roman Catholic priest who is director of the Westchester Institute for Ethics and the Human Person and a member of the Empire State Stem Cell Board"s ethics committee -- said that in the current economic recession, paying a woman $10,000 to participate in a research project is an "undue inducement." He added that he thinks it "manipulates women" and "creates a trafficking in human body parts." Other opponents of the decision questioned if compensating women who donate eggs for research is indeed equivalent to the process for infertility treatments. Jonathan Moreno, a professor of bioethics at the University of Pennsylvania, said that donors recognize that egg donation for infertility treatments is a "very concrete good for society" but that "you can"t be sure any biological material you collect for research wi

Daily Alcohol Intake Can Lead To Binge Drinking
Sipping wine, beer or spirits three to four times per week increases the risk of binge drinking, particularly among young men, according to a new study published in the journal Addiction. Researchers from the Universitçİ de Montrçİal and the University of Western Ontario analyzed the drinking habits of Canadians and found that frequent alcohol consumption can lead to binge drinking among all gender and all age groups.
News of the day
Teva Announces Approval And Launch Of Generic Urso 250(R) And Urso Forte(R)
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced that the U.S. Food and Drug Administration has granted approval for the Company"s Abbreviated New Drug Application (ANDA) for Ursodiol Tablets USP, 250 mg and 500 mg. Teva"s Ursodiol Tablets are the AB-rated generic equivalents of Axcan"s Urso 250® and Urso Forte®, which are indicated for treatment of patients with primary biliary cirrhosis. Shipment of this product has commenced.
Endocrinology

Blood Test Shows Statistically Significant Association With Alzheimer's Disease (AD), May Predict Conversion Of Mild Cognitive Impairment To AD

Dr. Zsuzsanna Nagy of the University of Birmingham presented data from a clinical study, funded by Cytox Limited, demonstrating that a simple blood-based biomarker discriminated between patients with Alzheimer"s disease (AD) and control subjects. The findings were statistically highly significant, and the test discriminated between the two groups with 80% sensitivity and 80% specificity. The results also showed that 40% of the mild cognitive impairment (MCI) patients tested had the same test results as AD patients. Follow up study of MCI patients enrolled in an earlier study found that the test allowed early identification of those MCI patients who later developed dementia. The results were presented at the 2009 Alzheimer"s Association International Conference on Alzheimer"s Disease (ICAD 2009), held in Vienna, Austria. The blood test measures the integrity of the cell cycle G1/S restriction point in peripheral blood lymphocytes. Dr. Nagy, the inventor of the test and scientific co-founder of Cytox Ltd, was the principal investigator of the study, which was conducted in collaboration with the Oxford Project to Investigate Memory and Aging (OPTIMA). According to Dr. Nagy, "The results of this study support the cell cycle hypothesis of Alzheimer"s disease - specifically, that G1/S cell cycle regulatory failure leads to the downstream development of the characteristic pathologies of the disease, the amyloid plaques and tau tangles. Most importantly, the findings validate the use of our lymphocyte test as a biomarker of Alzheimer"s disease and suggest that the test is predictive of cognitive deficit developing in MCI patients." About University of Birmingham The University of Birmingham is a world leading research-led institution and member of the elite Russell group of universities. Expertise within its five Colleges includes Medicine and Dentistry, Engineering and Physical Sciences, Life and Environmental Sciences, Social Sciences and Arts and Law. The University was one of the first civic universities, receiving its Royal Charter in 1900, and is one of the largest in the UK, with 27,000 students. The University of Birmingham is consistently ranked as a top UK university with a world presence and counts eight Nobel Prize winners amongst alumni and staff. According to the recent independent UK Research Assessment Exercise, nearly 90% of the University of Birmingham"s research activity has international impact. About Cytox Limited Cytox is a UK company developing products and services for neurodegenerative disorders. The company provides biomarker services to pharmaceutical industry clients conducting clinical trials with drugs for the treatment of Alzheimer"s disease (AD) and mild cognitive impairment (MCI). Cytox"s blood tests enable the prediction of which patients with MCI will develop AD. The biomarkers are based on the cell cycle hypothesis of AD and were invented by Dr. Zsuzsanna Nagy at the University of Oxford and the University of Birmingham. Cytox Limited


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):